KMT2A and acute myeloid leukemia: The presence of either AML1-ETO and PML-RARα fusion genes were associated with sensitivity to PARP inhibitors (olaparib and veliparib) whereas AML driven by MLL fusions were resistant to PARP inhibition (122).